Atara Biotherapeutics (ATRA) Stock Analysis & AI Equity Report
Atara Biotherapeutics (ATRA) overview
Atara Biotherapeutics (ATRA) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 121m and operating profit of USD 35.9m; the year-end share price was 18.09 USD and market capitalisation was USD 132m. Atara Biotherapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Atara Biotherapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Atara Biotherapeutics
Atara Biotherapeutics develops allogeneic T-cell immunotherapies for cancer and autoimmune diseases. Through a partnership with Pierre Fabre, it supports commercialization of Ebvallo in Europe and the United Kingdom for Epstein-Barr virus-positive post-transplant lymphoproliferative disease. In the United States, the FDA has accepted a resubmitted biologics license application for tab-cel, with a target action date in 2027.
Generate the Atara Biotherapeutics report
Atara Biotherapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Atara Biotherapeutics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Atara Biotherapeutics
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.